VYNDAMAX

This brand name is authorized in Hong Kong, Israel, United States

Active ingredients

The drug VYNDAMAX contains one active pharmaceutical ingredient (API):

1 Tafamidis
UNII 8FG9H9D31J - TAFAMIDIS

Tafamidis is a selective stabiliser of transthyretin (TTR). Tafamidis binds to TTR at the thyroxine binding sites, stabilising the tetramer and slowing dissociation into monomers, the rate-limiting step in the pathogenesis of transthyretin amyloidosis.

Read about Tafamidis

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
VYNDAMAX Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N07XX08 Tafamidis N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: HK Department of Health Drug Office Identifier(s): 66860
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 8550
Country: US FDA, National Drug Code Identifier(s): 0069-8730

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.